As combination therapies become the new standard in cancer care, experts believe cancer vaccines will be a critical component of the new treatment landscape. In this edition of Guided By Science, we explore the world of cancer vaccines and highlight anew approach to fight cancer with the natural power of our immune system.
New evidence suggests that tumor development is heavily influenced by our immune system. This theory, termed “cancer immuno-editing,” can be broken down into three phases: elimination, equilibrium, and escape. In this edition of Guided By Science, we explore the three phases of cancer immuno-editing to understand the battle between cancer and the immune system.
On behalf of the OncoSec team, we’re thrilled to announce the first patient enrolled in the Phase II Investigator Sponsored Trial led by the University of California, San Francisco (UCSF) to assess the safety and efficacy of the combination of our investigational therapy, ImmunoPulse™ IL-12, and Merck’s approved anti-PD-1 agent, KEYTRUDA® (pembrolizumab), in patients with unresectable metastatic melanoma.
Reports Spotlight Use of OMS ElectroImmunotherapy in Clinical Trial for Melanoma
SAN DIEGO, CA – July 23, 2012 – OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers, was spotlighted on Oakland television station KTVU-TV on July 20 and in the San Francisco Chronicle on July 18.
The KTVU segment aired during “Channel 2 News at 5.” KTVU health and science editor, John Fowler, provided a report on the clinical trial for melanoma currently underway at the University of California-San Francisco (UCSF), under the direction of principal investigator Dr. Adil Daud and in collaboration with OncoSec Medical. Dr. Daud, a patient enrolled in the clinical trial and Punit Dhillon, President and CEO of OncoSec, comment on the OMS ElectroImmunotherapy. The segment notes that OncoSec’s therapy is unique because although the electroporation treatment is local, it has shown to have an anti-cancer effect throughout the entire body.
The San Francisco Chronicle article, “Melanoma treatment shows promise at UCSF,” describes the features of the OMS ElectroImmunotherapy treatment and highlights clinical results to date, including the positive response of one of the patients enrolled in the clinical trial.
To watch the KTVU-TV report, please visit the following link:
To read the San Francisco Chronicle article in its entirety, please visit the following link: